HEALTH­CARE M&A OUT­LOOK BRIGHT IN 2018

BioSpectrum (Asia) - - Bio Content -

Over­all, Mea­ger and Ac­qui­si­tion (M&A) in the life­sciences sec­tor in Asia Pacific (APAC) is largely driven by do­mes­tic con­sol­i­da­tion, which ac­count for ap­prox­i­mately 90% of the deals. Com­pa­nies look­ing to in­crease cus­tomer base, op­ti­mize ca­pac­ity, in­crease as­set util­i­sa­tion, com­bine R&D re­sources and ex­pand dis­tri­bu­tion net­work are the key driv­ers of M&A in this sec­tor. Com­plex reg­u­la­tions and re­stric­tions for for­eign own­er­ship in many APAC coun­tries are lim­it­ing the num­ber of cross-bor­der trans­ac­tions. Hence, many global com­pa­nies are form­ing strate­gic part­ner­ships with re­gional and lo­cal play­ers. Greater China has con­sis­tently con­trib­uted to more than half of the deal vol­ume, fol­lowed by Ja­pan, In­dia and South Korea.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.